359 results on '"Robesti, D"'
Search Results
202. SC61 - Should we target all visible areas at mpMRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
203. SC58 - Are men with low risk prostate cancer but high pirads score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
204. SC57 - Multiparametric MRI of the prostate significantly underestimates tumor volume of small visible lesions. Implications for tailored focal therapy approaches
205. SC53 - Age and Gleason score upgrading between prostate biopsy and radical prostatectomy. Is this still true in the mp-MRI era?
206. SC56 - The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials
207. PT281 - The implementation of a prospective standardized postoperative complication system according to the EAU guidelines is associated with a decrease in the rate of adverse postoperative outcomes over time
208. A1057 - Assessing the impact of TURBT specimens review by a dedicated uropathologist on clinical decision making process: Results from a single tertiary referral center.
209. A0653 - Can we rely on available models to identify candidates for extended Pelvic Lymph Node Dissection (ePLND) in men staged with PSMA-PET? External validation of the Briganti nomograms and development of a novel tool to identify optimal candidates for ePLND
210. A0535 - The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer patients receiving atezolizumab: Analysis of individual participant data from IMvigor210 and IMvigor211.
211. A0290 - Oncologic outcomes of patients with incidental prostate cancer: Can we rely on multiparametric mri to exclude aggressive prostate cancer?
212. SC238 - Added value of concomitant systematic biopsies in predicting upgrading in patients with localized prostate cancer diagnosed by MRI-targeted biopsy: Implications for patient selection
213. SC227 - Development of a procedure-specific classification system for reporting postoperative complications in prostate cancer patients undergoing robot-assisted radical prostatectomy
214. SC182 - Which positive surgical margins features impact on the risk of prostate cancer specific mortality? A disease-tailored, competing-risk, long-term analysis
215. SC169 - Identifying the optimal postoperative strategies for clinically node positive patients treated with radical prostatectomy and extended pelvic lymph node dissection: Is androgen deprivation therapy always mandatory?
216. SC168 - Which patients with clinically node positive prostate cancer should be considered as candidates for radical prostatectomy as part of a multimodal treatment? The impact of nodal burden
217. SC127 - Added value of mpMRI, MRI-targeted and systematic biopsy in the prediction of adverse pathologic features in contemporary prostate cancer patients undergoing radical prostatectomy
218. SC37 - Do we really need detailed biopsy assessment of patients with low-risk prostate cancer candidate to active surveillance? A prospective validation of the ISUP recommendation
219. SC36 - Young men with low risk prostate cancer can be safely candidate to active surveillance regardless of the extent of biopsy involvement: Results from a single center series with pathological confirmation
220. PT388 - Long-term outcomes and patterns of recurrence in patients with clinical lymphadenopathies undergoing radical prostatectomy as part of a multimodal treatment
221. PT380 - Development of a procedure-specific classification system for reporting postoperative complications in prostate cancer patients undergoing robot-assisted radical prostatectomy
222. PT202 - Added value of mpMRI, MRI-targeted and systematic biopsy in the prediction of adverse pathologic features in contemporary prostate cancer patients undergoing radical prostatectomy
223. PT055 - Incremental utility of mp-MRI performed before confirmatory biopsy in reducing the risk of progression during active surveillance for men with low risk prostate cancer: Is imaging always useful?
224. PT038 - Do we really need detailed biopsy assessment of patients with low-risk prostate cancer candidate to active surveillance? A prospective validation of the ISUP recommendations
225. 1044 - Identifying the optimal postoperative strategies for clinically node positive patients treated with radical prostatectomy and extended pelvic lymph node dissection: Is androgen deprivation therapy always mandatory?
226. 651 - There is no way to compensate for a non-timely use of salvage radiation therapy in men with recurrent prostate cancer after radical prostatectomy
227. 589 - Which positive surgical margins features impact on the risk of prostate cancer specific mortality? A disease-tailored, competing-risk, long-term analysis
228. 465 - Young men with low risk prostate cancer can be safely candidate to active surveillance regardless of the extent of biopsy involvement: Results from a single center series with pathological confirmation
229. 216 - Which patients with clinically node positive prostate cancer should be considered as candidates for radical prostatectomy as part of a multimodal treatment? The impact of nodal burden
230. 1222 - Assessing the under-estimation of nodal tumour burden by 68Ga-PSMA and 11C-choline PET/CT scan in patients treated with salvage lymph node dissection for nodal recurrence of prostate cancer: A large multi-institutional analysis
231. 1098 - Impact of implementation of the EAU guidelines panel recommendations on reporting and grading of complications on perioperative outcomes after robot-assisted radical prostatectomy
232. 398 - Defining clinically meaningful positive surgical margins in patients undergoing radical prostatectomy for localized prostate cancer: A stage-by-stage analysis on the risk of clinical recurrence
233. 383 - Neutrophil to lymphocyte ratio is associated with lymph node invasion and higher nodal burden in contemporary high risk patients treated with radical prostatectomy and extended pelvic lymph node dissection
234. A1121 - The prognostic role of 68Ga-PSMA PET/CT and the impact of metastasis-directed therapy on cancer progression in men with biochemical recurrence from prostate cancer. Results from a large, single Institution series.
235. A0661 - Can pelvic lymph node dissection be omitted at the time of radical prostatectomy in patients with a negative preoperative 68Ga-PSMA PET/CT? The importance of patient risk stratification according to individual risk of lymph node metastases.
236. P255 - Natural history of patients affected by nodal recurrence from prostate cancer treated with salvage lymph node dissection without additional treatments.
237. P198 - Assessing the under-estimation of nodal tumour burden by 68Ga-PSMA and 11C-choline PET/CT scan in patients treated with salvage lymph node dissection for nodal recurrence of prostate cancer: A large multi-institutional analysis.
238. A0654 - Identifying the optimal candidates for a super-extended staging pelvic lymph-node dissection in prostate cancer patients treated in the PET-PSMA era. Results from a multi-institutional series.
239. A0818 - A novel PRECISE implemented predictive model to assess the risk of long-term disease reclassification in men on active surveillance. Results from a large, single institution series.
240. A0716 - Does the accuracy of PSA density change according to prostate volume? Assessing the diagnostic accuracy at the extreme values of prostate volume in a large single institution series.
241. A0715 - The importance of high volume providers in the diagnostic pathways of prostate cancer. Results from large, singe Institution series.
242. A0649 - Effect of Metastasis Directed Therapy (MDT) in men with PSMA PET detected recurrent prostate cancer according to time from primary treatment. Do men with late recurrences really benefit from MDT? Results from a large, single institution series.
243. A0612 - PSA doubling time thresholds in predicting clinical recurrence after biochemical recurrence in surgically treated prostate cancer patients. The Impact of nodal status and adjuvant radiotherapy.
244. A0610 - Identifying the optimal definition of PSA response after metastasis directed therapy in men with oligo-recurrent prostate cancer detected at PSMA PET.
245. A0511 - Age-dependent effect of early salvage radiotherapy for biochemical recurrence in prostate cancer patients treated with radical prostatectomy.
246. A0430 - External validation of the available nomograms for the identification of candidates for a staging extended pelvic lymph node dissection at the time of radical prostatectomy in prostate cancer patients preoperatively staged with PSMA PET.
247. A0365 - Cancer control rates in adequate versus inadequate treatment with adjuvant immunotherapy instillations with BCG.
248. P329 - How can we reduce the rates of false positive findings at mpMRI? The pivotal role of urologist expertise assessed in a large, single center series.
249. P311 - Towards a tailored use of PSA density to decide when to avoid prostate biopsy in men with PIRADS 3 lesions according to the location of the index lesion at mp-MRI. Results of a large, multi-institutional series.
250. P250 - Assessing the impact and timing of salvage radiation therapy in men with biochemically recurrent prostate cancer after radical prostatectomy and negative PSMA PET.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.